FINWIRES · TerminalLIVE
FINWIRES

Transcenta Says Ozekibart Found to Benefit Patients With Colorectal Cancer

By

Transcenta (HKG:6628) said updated data from the phase 1/2 study of ozekibart found the drug benefited patients with colorectal cancer and kept the disease at bay, according to a Thursday filing with the Hong Kong bourse.

The firm holds a license to develop and commercialize the drug in the greater China region.

Results published by the company's partner Inhibrx Biosciences showed the medicine had an objective response rate of 20% in patients who had been treated with other drugs previously.

The median progression-free survival among the 45 evaluable patients from the trial was 5.5 months, while the overall disease control rate stood at 87%.

Inhibrx plans to meet with the U.S. Food and Drug Administration in the second half of 2026 to discuss further trials of ozekibart in colorectal cancer.

Meanwhile, Inhibrx submitted a biologics license application with the U.S. Food and Drug Administration seeking approval for ozekibart in conventional chondrosarcoma, a type of bone cancer.

Related Articles

Asia

Marimaca's Drilling Results Show Mineralization At Chile Copper Deposit Appears Laterally Continuous Across High-Grade Area, Euroz Hartleys Says

Marimaca Copper's (ASX:MC2) latest drilling results continued to show that mineralization at the Pampa Medina copper prospect in Chile is not limited to isolated high-grade zones, but appears laterally continuous across the central high-grade area, Euroz Hartleys said in a note on Wednesday.Step-out drilling results from the Pampa Medina prospect reinforce the scale potential and continuity of the system. This demonstrates potential for Pampa Medina to develop into a large-scale, vertically extensive system.The combination of broad mineralized widths, higher-grade internal zones, and silver credits continues to support the potential for future bulk mining and a low-cost operation.At a copper price of around $5.80 per pound, the Marimaca oxide deposit would generate life-of-mine average earnings before interest, taxes, depreciation, and amortization of over $450 million per annum.The investment firm maintained its speculative buy recommendation on Marimaca Copper with a AU$16.94 per share price target.

ASX:MC2
Asia

Market Chatter: Australian Banks' May Reporting Season 'Underwhelming,' Operating Conditions Shifting Rapidly, Morgan Stanley Says

Australian banks' reporting season in May was "underwhelming" and they faced a rapid and material shift in operating conditions, according to Morgan Stanley analysts Richard Wiles and Sally Hong, the Australian Financial Review reported Wednesday.Morgan Stanley downgraded fiscal 2027 cash earnings-per-share estimates by 4% since March as revenue growth slows, credit demand weakens, and loan losses gradually rise, reversing an upgrade in February.Three hikes in the official cash rate, proposed changes to property-related tax measures in Australia's federal budget, as well as the impact of the global energy shock all contribute to the uncertainty in outlook for banks, per Morgan Stanley.The investment firm preferred ANZ Group Holdings (ASX:ANZ, NZE:ANZ) over Westpac Banking (ASX:WBC, NZE:WBC), National Australia Bank (ASX:NAB), and Commonwealth Bank of Australia (ASX:CBA).(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:ANZASX:CBAASX:NABASX:WBCNZE:ANZNZE:WBC
Asia

Market Chatter: Korea Exchange Plans to Launch Weekly Options on Single Stocks from June

South Korea's main equity exchange, the Korea Exchange, is planning to launch weekly options on single stocks from June, expiring on Thursdays, Bloomberg reported Wednesday.The exchange is also gearing up to launch monthly and weekly exchange trade fund (ETF) derivatives later in 2026, while expanding weekly options expiries for the Kospi 200 and Kosdaq 150 indexes to Tuesdays, Wednesdays, and Fridays from the current schedule of Mondays and Thursdays, the report said.The country's main bourse Korea Composite Stock Price Index or Kospi is driven by gains made by heavyweight chipmakers Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660), which led it to surge nearly 70% on a year-to-date basis. This surge has made the Kospi the world's best-performing major equity index, it said.Shares of Samsung Electronics fell nearly 3% in recent trade.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

^KOSDAQKOSPIKRX:000660KRX:005930